Cost-effectiveness of asthma therapy: a comprehensive review

References

• Executive Committee GEMA 2009. GEMA2009 (Spanish guideline on the management of asthma). J Investig Allergol Clin Immunol 2010;20:1–59
   PubMedGoogle Scholar
• Kim YM, Kim YS, Jeon SG, Kim YK. Immunopathogenesis of allergic asthma: more than the Th2 hypothesis. Allergy Asthma Immunol Res 2013;5:189–196
   PubMed Web of Science ®Google Scholar
• Anandan C, Nurmatov U, van Schayck OC, Sheikh A. Is the prevalence of asthma declining? Systematic review of epidemiological studies. Allergy 2010;65:152–167
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Laviotte M, Rubin AS, Fiterman J, Lapa E Silva JR, Shah PL, Fiss E, et al. Bronchial thermoplasty: long-term safety and effectiveness in patients with severe persistent asthma. J Allergy Clin Immunol 2013;132:1295–1302
   PubMed Web of Science ®Google Scholar
• Song WJ, Kang MG, Chang YS, Cho SH. Epidemiology of adult asthma in Asia: toward a better understanding. Asia Pac Allergy 2014;4:75–85
   PubMedGoogle Scholar
• Price P, Fletcher M, Van der Molen T. Asthma control and management in 8.000 European patients: the REcogniseAsthma and Link to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med 2014;24:14009
   PubMed Web of Science ®Google Scholar
• Dal Negro RW, Michetto C, Tosatto R, Dionisi M, Turco P, Donner CF. Costs of asthma in Italy: results of the SIRIO (Social Impact of Respiratory Integrated Outcomes) study. Respir Med 2007;101:2511–19
   PubMed Web of Science ®Google Scholar
• To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, Boulet LP. Global asthma prevalence in adults: findings from cross-sectional world health survey. BMC Public Health 2012;12:204
   PubMed Web of Science ®Google Scholar
• Quirce S. Asthma in Alergologica 2005. J Investig Allergol Clin Immunol 2009;19:14–20
   PubMed Web of Science ®Google Scholar
• Arnedo-Pena A, García-Marcos L, Bercedo-Sanz A, Aguinaga-Ontoso I, González-Díaz C, García-Merino A, Busquets-Monge R, et al. Prevalence of asthma symptoms in schoolchildren and climate in Western European countries: an ecological study. Int J Biometeorol 2013;57:775–784
   PubMed Web of Science ®Google Scholar
• Carreras M, Garcia-Goñi M, Ibern P, Coderch J, Vall-Llosera L, Inoriza JM. Estimates of patient costs related with population morbidity: can indirect costs affect the results? Eur J Health Econ 2011;12:289–295
   PubMed Web of Science ®Google Scholar
• Patel MR, Nelson BW, Id-Deen E, Caldwell C. Beyond co-pays and out-of-pocket costs: perceptions of health-related financial burden in managing among African American women. J Asthma 2014; 51:1083–1088
   PubMed Web of Science ®Google Scholar
• Higgings JPT, Green S. Cochrane handbook for systematic reviews of interventions: current version 5.1.0 (updated March 2011). The Cochrane Collaboration 2011. Available from: www.cochrane.org/handbook [last accessed 27 Nov 2014]
   Google Scholar
• Accordini S, Corsico AG, Braggion M, Gerbase MW, Gislason D, Gulsvik A, Heinrich J, et al. The cost of persistent asthma in Europe: an international population-based study in adults. Int Arch Allergy Immunol 2013;160:93–101
   PubMed Web of Science ®Google Scholar
• Simpson CR, Sheikh A. Trends in the epidemiology of asthma in England: a national study of 333,294 patients. J R Soc Med 2010;103:98–106
   PubMed Web of Science ®Google Scholar
• Rely K, McQuire SE, Alexandre PK, Escudero GS. Cost effectiveness of treatment with salmeterol/fluticasone compared to montelukast for the control of persistent asthma in children. Value Health 2011;14:S43–S47
   Google Scholar
• Martínez-Moragón E, Serra-Batlles J, De Diego A, Palop M, Casan P, Rubio-Terrés C, Pellicer C; por el Grupo de Investigadores del estudio AsmaCost. Economic cost of treating the patient with asthma in Spain: the AsmaCost study. Arch Bronconeumol 2009;45:481–486
   PubMed Web of Science ®Google Scholar
• Ojeda P, Sanz de Burgoa V; Coste Asma Study. Costs associated with workdays lost and utilization of health care resources because of asthma in daily clinical practice in Spain. J Investig Allergol Clin Immunol 2013;23:234–241
   PubMed Web of Science ®Google Scholar
• Blasco Bravo AJ, Perez-Yarza EG, Lázaro Y de Mercado P, Bonillo-Perales A, Díaz-Vázquez CA, Moreno- Galdós A. Coste del asma en pediatría en España: un modelo de evaluación de costes basado en la prevalencia. An Pediatr (Barc) 2011;74:145–153
   PubMed Web of Science ®Google Scholar
• Serra-Batlles J, Plaza V, Comella A. Changes in clinical, pulmonary function, quality of life and costs in a cohort of asthmatic patients followed for 10 years. Arch Bronconeumol 2011;47:482–487
   PubMed Web of Science ®Google Scholar
• Kauppi P, Linna M, Martikainen J, Makela MJ, Haahtela T. Follow-up of the Finnish Asthma Programme 2000–2010: reduction of hospital burden needs risk group rethinking. Thorax 2013;68:292–293
   PubMed Web of Science ®Google Scholar
• Martinez-Moragon E. Impacto económico y coste-efectividad del tratamiento del asma grave. In: Plaza Moral V, López Viña A, Quirce Gancedo S, ed. Asma grave y asma de control difícil. Programa Ulises. Madrid: Saned Grupo 2013;4:67–84
   Google Scholar
• Akibami LJ, Sullivan SD, Campbell JD, Grundmeier RW, Hartert TV, Lee TA, Smith RA. Asthma outcomes: healthcare utilization and costs. J Allergy Clin Immunol 2012;129:49–64
   Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE; 2008
   Google Scholar
• Rodriguez-Martinez CE, Nino G, Castro-Rodriguez JA. Cost-utility analysis of daily versus intermittent inhaled corticosteroids in mild-persistent asthma. Pediatr Pulmonol 2014. [Epub ahead of print]. doi: 10.1002/ppul.23073
   Web of Science ®Google Scholar
• Johansson G, Sondhi PM. Cost effectiveness analysis of salmeterol/fluticasone propionate 50/100 ug vs. fluticasone propionate 100ug in adults and adolescents with asthma III: results. Pharmacoeconomics 1999;16:15–21
   Web of Science ®Google Scholar
• Andersson F, Stalhl E, Barnes PJ, Moller C, Arheden L. Adding formoterol to budesonide in moderate asthma – health economic results from the FACET study. Respir Med 2001;95:505–512
   PubMed Web of Science ®Google Scholar
• Ericsson K, Bantje TA, Huber RM, Borg S, Bateman ED. Cost-effectiveness analysis of budesonide/formoterol compared with fluticasone in moderate-persistent asthma. Respir Med 2006;100:586–594
   PubMed Web of Science ®Google Scholar
• Fritscher L, Chapman KR. Seretide: a pharmacoeconomic analysis. J Med Econ 2008;11:555–570
   PubMedGoogle Scholar
• Sheth K, Borker R, Emmett A, Rickard K, Dorinsky P. Cost effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma. Pharmacoeconomics 2002;20:909–918
   PubMed Web of Science ®Google Scholar
• Rosenhall L, Borg S, Andersson F, Ericsson K. Budesonide/formoterol in a single inhaler (Symbicort) reduces healthcare costs compared with separate inhalers in the treatment of asthma over 12 months. Int J Clin Pract 2003;57:662–667
   PubMed Web of Science ®Google Scholar
• Johansson G, Andreasson EB, Larsson PE, Vogelmeier CF. Cost-effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics 2006;24:695–708
   PubMed Web of Science ®Google Scholar
• Quirce S, Barcina C, Plaza V, Calvo E, Muñoz M, Ampudia R, Capel M. A comparison of budesonide/formoterol maintenance and reliever therapy versus conventional best practice in asthma management in Spain. J Asthma 2011;48:839–847
   PubMed Web of Science ®Google Scholar
• Price D, Small I, Haughney J, Ryan D, Gruffydd-Jones K, Lavorini F, Harris T, et al. Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclomethasone-formoterol: a retrospective study of real-world patients. Prim Care Respir J 2013;22:439–448
   PubMedGoogle Scholar
• Gerzeli S, Rognoni C, Quaglini S, Cavallo MC, Cremonesi G, Papi A. Cost-effectiveness and cost-utility of beclomethasone/formoterol versus fluticasone propionate/salmeterol in patients with moderate to severe asthma. Clin Drug Investig 2012;32:253–265
   PubMed Web of Science ®Google Scholar
• Antoniu SA, Antohe I. Evaluation of inhaled tiotropium in asthma uncontrolled with standard combination therapy. Expert Opin Pharmacother 2013;14:967–969
   PubMed Web of Science ®Google Scholar
• Albertson TE, Schivo M, Gidwani N, Kenyon NJ, Sutter ME, Chan AL, Louie S. Pharmacotherapy of critical asthma syndrome: current and emerging therapies. Clin Rev Allergy Immunol 2013. [Epub ahead of print]. doi:10.1007/s12016-013-8393-8
   PubMed Web of Science ®Google Scholar
• Guyer AC, Long AA. Long-acting anticholinergics in the treatment of asthma. Curr Opin Allergy Clin Immunol 2013;13:392–398
   PubMed Web of Science ®Google Scholar
• Adams KS, Lowe DK. Tiotropium for adults with inadequately controlled persistent asthma. Ann Pharmacother 2013;47:117–123
   PubMed Web of Science ®Google Scholar
• Kerstjens HA, Engel M, Dahl R, Paggiaro P, Beck E, Vanderwalker M, Sigmund R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012;367:1198–1207
   PubMed Web of Science ®Google Scholar
• Peters SP, Kunselman SJ, Icitovic N, Moore WC, Pascual R, Ameredes BT, Boushey HA, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Eng J Med 2010;363:1481–1488
   Web of Science ®Google Scholar
• Willson J, Bateman ED, Pavord I, Lloyd A, Krivasi T, Esser D. Cost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting B-agonists. Appl Health Econ Health Policy 2014;12:447–459
   PubMedGoogle Scholar
• Hankin CS, Cox L. Allergy immunotherapy: what is the evidence for cost saving? Curr Opin Allergy Clin Immunol 2014;14:363–370
   PubMed Web of Science ®Google Scholar
• Brüggenjürgen B, Reinhold T, Brehler R, Laake E, Wiese G, Machate U, Willich SN. Cost-effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic asthma. Ann Allergy Asthma Immunol 2008;101:316–324
   PubMed Web of Science ®Google Scholar
• Reinhold T, Ostermann J, Thum-Oltmer S, Brüggenjürgen B. Influence of subcutaneous specific immunotherapy on drug costs in children suffering from allergic asthma. Clin Transl Allergy 2013;3:30
   PubMedGoogle Scholar
• Simoens S. The cost-effectiveness of immunotherapy for respiratory allergy: a review. Allergy 2012;67:1087–1105
   PubMed Web of Science ®Google Scholar
• Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy ClinImmunol 2005;115:459–465
   PubMed Web of Science ®Google Scholar
• Nopp A, Johansson SG, Ankerst J, Palmqvist M, Öman H. CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment. Allergy 2007;62:1175–1181
   PubMed Web of Science ®Google Scholar
• D’ Amato G, Stanziola A, Sanduzzi A, Liccardi G, Salzillo A, Vitale C, Molino A, et al. Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review. Multidiscip Respir Med 2014;9:23
   Google Scholar
• Burch J, Griffin S, McKenna C, Walker S, Paton J, Wright K, Woolacott N. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6–11 years. Pharmacoeconomics 2012;30:991–1004
   PubMed Web of Science ®Google Scholar
• Diaz RA, Charles Z, George E, Adler AI. NICE guidance on omalizumab for severe asthma. Lancet Respir Med 2013;1:189–90
   Google Scholar
• Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy ClinImmunol 2004;114:265–269
   PubMed Web of Science ®Google Scholar
• Dewilde S, Turk F, Tambour M, Sandstrom T. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr Med Res Opin 2006;22:1765–1776
   PubMed Web of Science ®Google Scholar
• Wu AC, Paltiel AD, Kuntz KM, Weiss ST, Fuhlbrigge AL. Cost-effectivenes of omalizumab in adults with severe asthma: results from the Asthma Policy Model. J Allergy Clin Immunol 2007;120:1146–1152
   PubMed Web of Science ®Google Scholar
• Dal Negro RW, Pradelli L, Tognella S, Micheletto C, Iannazzo S. Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy. Eur Ann Allergy Clin Immunol 2011;43:45–53
   PubMedGoogle Scholar
• Van Nooten F, Stern S, Braunstahl GJ, Thompson C, Groot M, Brown RE. Cost-effectiveness of omalizumab for uncontrolled allergic asthma. J Med Econ 2013;16:342–348
   PubMedGoogle Scholar
• Brown R, Turk F, Dale P, Bousquet J. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy 2007;62:149–153
   PubMed Web of Science ®Google Scholar
• Costello RW, Long DA, Gaine S, Mc Donnell T, Gilmartin JJ, Lane SJ. Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs. Ir J Med Sci 2011;180:637–641
   PubMed Web of Science ®Google Scholar
• Dal Negro RW, Tognella S, Pradelli L. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy. J Asthma 2012;49:843–848
   PubMed Web of Science ®Google Scholar
• Menzella F, Facciolongo N, Piro R, Formisano D, Roggeri A, Simonazzi A, et al. Clinical and pharmacoeconomic aspects of omalizumab: a 4 year follow-up. Ther Adv Respir Dis 2012;6:87–95
   PubMed Web of Science ®Google Scholar
• Levy AN, Ruiz J, Garcia A, Soler Garcia-Agua N, Sanjuan Hidalgo MV. Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective. J Asthma 2014. [Epub ahead of print]. doi:10.3109/02770903.2014.941474
   PubMed Web of Science ®Google Scholar
• Campbell JD, Spackman DE, Sullivan SD. The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective. Allergy 2010;65:1141–1148
   PubMed Web of Science ®Google Scholar